Photo = Getty Image Bank
SK Bioscience(147,500 -11.41%)Sat down to the 150,000 won range. Due to the spillover of profit-taking sales centered on foreigners and institutions, ants are concerned about the loss of ants.
As of 10:34 am on the 22nd, SK Bioscience is trading at 147,000 won, down 19,500 won (11.71%) from the previous day. It fell to 146,000 won during the intraday, recording a record low. Currently, it is tentatively counted that foreigners are net selling 34,000 shares.
It can be interpreted as falling for the second day as profit-taking sales were released. SK Biosciences also fell 1.48% on the 19th, the second day of listing.
This downward trend is interpreted as a result of the profit-taking of foreigners and institutional investors. Foreigners sold 136.3 billion won worth of money over two days, and institutional investors also made profits by net selling 42.9 billion won.
On the other hand, most individual investors are recording negative (-) returns. Individual investors have bought stocks worth 1976 billion won by making net purchases from the day of listing.
One individual investor said, “I bought 300 shares on the news that I’m going to go, but my losses are only growing,” and said, “The account is likely to evaporate.”
Another investor said, “I recorded a minus 15%, but I just lost it,” and said, “I won’t do it again.”
It is expected that it will take more time for the share price to rebound. The industry believes that the stock price can turn upward only after tangible business results. SK Bioscience plans to release a novel coronavirus infection (Corona 19) vaccine in the first half of next year. One of the candidate substances,’NBP 2001′, has been undergoing phase 1 clinical trials since November last year, and GBP510, which is being developed with the support of the Bill Gates Foundation and CEPI, is also undergoing phase 1/2 clinical trials.
Han Byeong-hwa, a researcher at Eugene Investment & Securities, said, “If the data of phase 2 and 3 of the self-developed COVID-19 vaccine is good and can be released in the second half of next year, the market cap of global new vaccine companies such as Curevec NovaVax BioEntech, etc. ), the share price is expected to be formed.”
Earlier, on the 18th, the first day of listing, SK Bioscience entered the stock market splendidly with a record (double the public offering price on the first day of listing, and the upper limit after the initial price was formed). The market cap also recorded 12.900 trillion won, ranking in the top 28 of the KOSPI.
Eunbit Go, reporter Hankyung.com [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution